{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:06:56Z","timestamp":1793855216952,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/501100002141","name":"UK Health Security Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vaccine.2025.127870","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:42:47Z","timestamp":1761234167000},"page":"127870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England"],"prefix":"10.1016","volume":"67","author":[{"given":"Nurin","family":"Abdul Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freja C.M.","family":"Kirsebom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127870_bb0005","author":"GOV.UK [Internet]"},{"issue":"262","key":"10.1016\/j.vaccine.2025.127870_bb0010","article-title":"Investigating the FLiRT variants of COVID-19: is it an emerging concern?","author":"Aden","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127870_bb0015","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2023.02.020","article-title":"Assessing COVID-19 vaccine effectiveness against omicron subvariants: report from a meeting of the World Health Organization","volume":"41","author":"Feikin","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127870_bb0020","author":"GOV.UK [Internet]"},{"key":"10.1016\/j.vaccine.2025.127870_bb0025","author":"GOV.UK [Internet]"},{"key":"10.1016\/j.vaccine.2025.127870_bb0030","article-title":"Effectiveness of the Sanofi\/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original\/Omicron BA.4-5) bivalent vaccines against hospitalisation in England","volume":"71","author":"FCM","year":"2024","journal-title":"eClinicalMedicine [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127870_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106177","article-title":"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","volume":"89","author":"Kirsebom","year":"2024","journal-title":"J Inf"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127870_bb0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127870_bb0045","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1473-3099(23)00365-1","article-title":"Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study","volume":"23","author":"Kirsebom","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127870_bb0050","author":"GOV.UK [Internet]"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127870_bb0055","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.vaccine.2025.127870_bb0060","first-page":"0","article-title":"Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study","volume":"0","author":"Kirsebom","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127870_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2022.104974","article-title":"Monitoring the COVID-19 immunisation programme through a national immunisation management system \u2013 England\u2019s experience","volume":"170","author":"Tessier","year":"2023","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.vaccine.2025.127870_bb0070","author":"GOV.UK [Internet]"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127870_bb0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/EDE.0000000000001484","article-title":"Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case\u2013Control Studies of COVID-19 Vaccine Effectiveness","volume":"33","author":"Hitchings","year":"2022","journal-title":"Epidemiology"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127870_bb0080","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S1473-3099(23)00575-3","article-title":"Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant","volume":"23","author":"Uriu","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127870_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127870_bb0090","article-title":"Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127870_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-025-02139-5","article-title":"Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages","volume":"10","author":"Yang","year":"2025","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127870_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29417","article-title":"Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations","volume":"96","author":"Yang","year":"2024","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127870_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2024.2428800","article-title":"Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the omicron BA.2.86\/JN.1 period among older adults in seven European countries: a VEBIS-EHR network study","volume":"23","author":"Nunes","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127870_bb0110","article-title":"Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform","volume":"79","author":"Nguyen","year":"2025","journal-title":"eClinicalMedicine [Internet]"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127870_bb0115","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","article-title":"Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127870_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00079-9","article-title":"Virological characteristics of the SARS-CoV-2 LP.8.1 variant","volume":"25","author":"Chen","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127870_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126961","article-title":"mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice","volume":"54","author":"Lee","year":"2025","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127870_bb0130","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","article-title":"Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC","volume":"24","author":"Arora","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127870_bb0135","article-title":"Interim Estimates of 2024\u20132025 COVID-19 Vaccine Effectiveness Among Adults Aged \u226518 Years \u2014 VISION and IVY Networks, September 2024\u2013January 2025","volume":"74","author":"Link-Gelles","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep [Internet]"},{"key":"10.1016\/j.vaccine.2025.127870_bb0140","series-title":"Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish Nationwide register-based cohort study [internet]","author":"Hansen","year":"2025"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:28:23Z","timestamp":1763324903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25011673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"alternative-id":["S0264410X25011673"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127870","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127870"}}